MOMO'S BREAKOUT BOARD

[EHRjunkie]

$HALB $0.01 OS 565M MC 5.8M

Is testing at Mississippi State University a nasal spray (patent pending) to treat PTSD, ALZHEIMER's, EPILEPSY

JACKSON CENTER, PA / ACCESSWIRE / May 2, 2023 / Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of this study by Halberd and Mississippi State University is to discover the effectiveness of the nasal spray against multiple antigens, linked to head trauma and various neurodegenerative conditions like PTSD, Alzheimer's Disease, early onset Alzheimer's Disease, and Epilepsy.

https://www.otcmarkets.com/stock/HALB/news/Halberd-HALB-Pursuing-a-Nasal-Spray-to-Counteract-the-Effects-of-Head-Trauma?id=398900